Employing End Tidal Capnography in Continuous Flow Ventricular Assist Device Patients

Withdrawn before enrolling · Not applicable

Conditions studied: Cardiomyopathy, Cardiovascular Disease, Heart Disease

In brief

The purpose of this study is to explore how the End Tidal Carbon Dioxide monitoring via nasal cannula (ETCO2-NC) device may allow for earlier detection of respiratory complications. This device will detect the amount of carbon dioxide exhaled with each breath and may better predict high levels of this than traditional monitoring. This may reduce the number and severity of respiratory issues. A convenience sample of 60 participants either scheduled for continuous flow left ventricular assist device (CF-LVAD) implant or who have been readmitted to an ICU with a CF-LVAD will be recruited and randomized to usual care or usual care plus ETCO2-NC throughout their stay in the ICU.

Key facts

Study ID

NCT02838355

Run by

Emory University

People needed

0

Starts

2016-10-01

Expected to finish

2018-02-01

Last updated by the study team

2018-03-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Scheduled for mechanical circulatory support device (MCSD) implant or have been readmitted to an intensive care unit (ICU) with a continuous flow left ventricular assist device (CF-LVAD)
• New York Heart Association (NYHA) functional class III to IV
• Ability to read, write, and speak English

You may not qualify if…

• Requiring mechanical ventilation during the active phase of the trial

Where it is running

• Emory University Hospital — Atlanta, Georgia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.